CELSR2 and central nervous system cancer: Meanwhile, although CELSR2 expression was significantly upregulated in Grade 2, Grade 3 and recurrent Grade 4 gliomas, a significantly shorter survival time was only observed in patients with elevated CELSR2 mRNA levels specifically in Grade 3 gliomas and recurrent Grade 4 gliomas (Fig. 1G, H; Supplementary Fig. 1B–D).